Calithera Biosciences (NASDAQ:CALA) reported quarterly losses of $(2.01) per share which missed the analyst consensus estimate of $(1.93) by 4.15 percent. This is a 33 percent increase over losses of $(3.00) per share from the same period last year.
NIO Q4 EPS $(0.21), Inline, Sales $1.55B Beat $1.53B Estimate
NIO (NYSE:NIO) reported quarterly losses of $(0.21) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.14) per share from the same period last year. The company reported
